Download MendeleyDiscovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ER alpha + Breast Cancer.
Burks, H.E., Abrams, T., Kirby, C.A., Baird, J., Fekete, A., Hamann, L.G., Kim, S., Lombardo, F., Loo, A., Lubicka, D., Macchi, K., McDonnell, D.P., Mishina, Y., Norris, J.D., Nunez, J., Saran, C., Sun, Y., Thomsen, N.M., Wang, C., Wang, J., Peukert, S.(2017) J Med Chem 60: 2790-2818
- PubMed: 28296398
- DOI: https://doi.org/10.1021/acs.jmedchem.6b01468
- Primary Citation of Related Structures:
5T92, 5T97 - PubMed Abstract:
Tetrahydroisoquinoline 40 has been identified as a potent ERα antagonist and selective estrogen receptor degrader (SERD), exhibiting good oral bioavailability, antitumor efficacy, and SERD activity in vivo. We outline the discovery and chemical optimization of the THIQ scaffold leading to THIQ 40 and showcase the racemization of the scaffold, pharmacokinetic studies in preclinical species, and the in vivo efficacy of THIQ 40 in a MCF-7 human breast cancer xenograft model.
Organizational Affiliation:
Novartis Institutes for BioMedical Research , 181 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
